miR29a-Loaded Extracellular Vesicles Derived from Human Mesenchymal Stem Cells Inhibit Fibrotic and Inflammatory...

Area of Science:

• Biomedical Engineering
• Cell Biology
• Molecular Medicine

Background:

• Fibrotic diseases, characterized by excessive extracellular matrix deposition, cause significant mortality.
• Tissue stiffening in fibrosis activates YAP/TAZ and NFκB pathways, promoting disease progression.
• MicroRNAs (miRNAs), particularly the miR29 family, show potential for reversing fibrotic processes.

Purpose of the Study:

• To investigate the therapeutic potential of mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) loaded with an antifibrotic miR29a mimic.
• To evaluate the impact of these engineered EVs on fibrotic and inflammatory signaling in human dermal fibroblasts.

Main Methods:

• Human MSCs were engineered to overexpress a miR29a mimic.
• MSC-derived EVs were isolated and characterized.
• EVs loaded with miR29a mimic were used to treat human dermal fibroblasts.
• Fibrotic and inflammatory markers, including YAP activation and NFκB signaling, were assessed.

Main Results:

• miR29a mimic reduced YAP activation in MSCs on stiff substrates.
• Engineered EVs successfully delivered miR29a mimic to target cells.
• miR29a-loaded EVs significantly reduced inflammatory signaling in fibroblasts.
• The contractile phenotype of human dermal fibroblasts was diminished by miR29a-loaded EVs.

Conclusions:

• MSC-derived EVs can be effectively loaded with miR29a mimic for therapeutic delivery.
• miR29a-loaded EVs demonstrate antifibrotic and anti-inflammatory effects in vitro.
• This approach holds promise for developing novel therapies against fibrotic diseases.